Skip to main content
. 2011 Aug 18;6(8):e23758. doi: 10.1371/journal.pone.0023758

Figure 6. Ki-67 expression in BM aspirates is higher in CLL samples from high-risk patients, and VLA-4 negative and CD38 positive subclones express higher levels of Ki-67 in BM.

Figure 6

MNCs from BM aspirates of CLL patients were stained with anti-CD19-PC7, CD5-PC5 and either VLA-4-PE or CD38-PE or respective isotype control-PE antibody and intracellulary stained with Ki-67-FITC or isotype control before flow cytometric analysis. (A) Left. Difference in Ki-67 expression in CLL samples from VLA-4 low (n = 6) and high-risk (n = 6, Unpaired t-test, p = .0298) patients as well as CD38 low (n = 5) and high-risk patients (n = 7, Unpaired t-test, p = .0278). Right. Difference in Ki-67 expression in CLL cells from patients with a combined low risk (-/-, VLA-4-/CD38-, n = 4), with discordant VLA-4 and CD38 risk (+/− −/+, n = 3), and VLA-4+/CD38+ (+/+, n = 5, ANOVA, One-way analysis of variance, p = .0233, Bonferroni's multiple comparision test). (B) Representative plot of CLL cells (CD19+/CD5+) analysed for their VLA-4 expression. VLA-4 negative and VLA-4 positive CLL cells were gated and further analyzed for their Ki-67 expression. (C) Representative plots for CD38 analysis. Percentage of Ki-67+ CLL cells in (A, right) VLA-4 negative and VLA-4 positive subclones within individual patients (n = 12, Paired t-test, p = .0275) or in (B, right) CD38 negative and CD38 positive subclones (n = 12, Paired t-test, p = .0048). neg, negative subclones; pos, positive subclones. *, P<.05; **, P<.01.